Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

麗珠醫藥集團股份有限公司
LIVZON PHARMACEUTICAL GROUP INC.*
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 1513)

APPOINTMENT OF MEMBERS OF THE STRATEGY COMMITTEE AND THE NOMINATION COMMITTEE OF THE BOARD

The board (the "**Board**") of directors (the "**Director(s)**") of Livzon Pharmaceutical Group Inc.* 麗珠醫藥集團股份有限公司 (the "**Company**") hereby announces that on March 24, 2026, Ms. Ran Yongmei, the employee representative Director of the Company, has been appointed as a member of the Strategy Committee of the Board, and Mr. Tang Yanggang, the executive Director of the Company, has been appionted as a member of the Nomination Committee of the Board, which became effective from March 24, 2026.

Save as disclosed above, there is no other change in the composition of the Board committees. For details of the membership information of the Board committees on which each Board member serves, please refer to the list of positions held by current directors at the board and the board committees announcement published by the Company on the same day.

By order of the Board
Livzon Pharmaceutical Group Inc.*
麗珠醫藥集團股份有限公司
Liu Ning
Company Secretary

Zhuhai, China
24 March 2026

As at the date of this announcement, the Executive Directors of the Company are Mr. Tang Yanggang (Vice Chairman); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Lin Nanqi and Mr. Qiu Qingfeng; the Employee Representative Director is Ms. Ran Yongmei; and the Independent Non-Executive Directors of the Company are Mr. Bai Hua, Mr. Luo Huiyuan, Ms. Cui Lijie and Ms. Wang Zhiyao.

* *For identification purpose only*